What this study is
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
What's being tested
- [C-11]PiB-PET/MRI
Intervention · DRUG
All study participants will undergo brain imaging with [C-11]PiB-PET/MRI. [C-11]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
Study details
- Sponsor
- University of Alabama at Birmingham
- Conditions
- Alzheimer Disease
- Enrolling
- 160 people
- Starts
- 2018-04-20
- Est. completion
- 2028-10
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 50 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
- Negative urine or serum B-hCG test within 2 days of [C-11]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
You can't join if
- Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
- Inability or contraindication for undergoing MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of dementia
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Alabama at Birmingham Medical Center
Birmingham, Alabama, United States
- Jonathan McConathy, MD · Contact205-996-7115jmcconathy@uabmc.edu
- Jonathan McConathy, MD, PhD · Principal investigator
- Geldmacher David, MD · Sub-investigator
- Lapi Suzanne, PhD · Sub-investigator
- Jeffers Charlotte Denise, RPh · Sub-investigator
- Natelson Marissa, MD · Sub-investigator
- Roberson Erik, MD, PhD · Sub-investigator
Recruiting
Study team
Sponsor
University of Alabama at Birmingham
Study ID IRB-300001005
Principal investigator
Jonathan McConathy, MD
University of Alabama at Birmingham
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.